Samsung Bioepis Launches PYZCHIVA® (Biosimilar to Stelara) in the US Samsung Bioepis Co., Ltd. has announced the U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab). PYZCHIVA is approved…
Neuroendocrine Tumor Center of Excellence Re-Certified The Center for Neuroendocrine Tumors at the Bad Berka Central Clinic has been officially re-certified, continuing its distinction as a leading medical facility in…
Prisma Health Saves $450M with Systemwide Transformation Prisma Health, South Carolina’s largest healthcare provider, has long been at the forefront of delivering exceptional care across the state. However, the challenges…
Baxter Reports Q4 and Full-Year 2024 Results Baxter International Inc. (NYSE: BAX), a leader in the global medtech industry, reported its financial results for the fourth quarter and full year…
Celltrion Presents New LIBERTY Study Analyses at ECCO Congress on SC Infliximab Efficacy and Safety Celltrion presented new post hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) at…
CareDx Study Shows AlloSeq cfDNA Accurately Detects Organ Rejection CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, announced new findings published in Transplant International. The study…
Precision BioSciences Announces Early Safety and Antiviral Results for PBGENE-HBV in ELIMINATE-B Trial Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform…
WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the European Commission (EC) has…
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case An International Chamber of Commerce (ICC) tribunal has issued a partial final award in favor of AOP Orphan…
Abridge Secures $250M Series D, Unveils New Contextual Reasoning Engine for Healthcare Abridge, a leader in generative AI for clinical conversations, has secured a $250 million Series D funding round.…
Two Dedicated Team Members Awarded the Graeme Rabbits Scholarship Two deserving individuals are one step closer to achieving their career aspirations in behavioural neuroscience and social work, thanks to receiving…
Samsung Bioepis Gains EC Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™) Samsung Bioepis Co., Ltd. has announced that the European Commission (EC) has granted marketing authorization for two denosumab biosimilars, OBODENCE™…